Literature DB >> 14576473

Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer.

Jinru Shia1, Nathan A Ellis, Philip B Paty, Garrett M Nash, Jing Qin, Kenneth Offit, Xin-Min Zhang, Arnold J Markowitz, Khedoudja Nafa, Jose G Guillem, W Douglas Wong, William L Gerald, David S Klimstra.   

Abstract

Identification of colorectal carcinomas with high levels of DNA microsatellite instability (MSI-H) is important because of the suggested prognostic and therapeutic significance associated with MSI. The role of histology in identifying MSI-H colorectal carcinomas has been suggested by some studies but not confirmed by others. Furthermore, previous studies assumed that hereditary nonpolyposis colorectal cancer (HNPCC)-associated MSI-H tumors and sporadic MSI-H tumors have similar histology. This assumption, however, has been challenged by more recent studies. In this report, we first analyzed the value of various histologic features in predicting MSI-H in a series of 218 colorectal carcinomas containing mixed HNPCC and sporadic cases [77 tumors (35%) were MSI-H by polymerase chain reaction (PCR) method]. Then, we evaluated the various histologic features comparatively in two groups extracted from the 218 cases. Group A was composed of 84 tumors from 82 patients obtained based on a strong family history (HNPCC/HNPCC-like group) (male to female ratio, 42:40; age range, 23-80 years, median, 53.5 years). Thirty-one of the 84 tumors (41.7%) were MSI-H by PCR, and all 31 cases were HNPCC by Amsterdam criteria. Group B was composed of 109 patients with no family history of colorectal cancer or HNPCC-associated cancer, obtained from surgical clinics (sporadic group) (male to female ratio, 65:69; age range, 31-84 years, median, 65 years). Thirty-five of the 109 tumors (32.1%) were MSI-H by PCR. Our results showed that, overall, poor tumor differentiation, medullary type, mucinous type, signet-ring cell component, histologic heterogeneity, and increased tumor-infiltrating lymphocytes (TILs) were features more commonly seen in MSI-H tumors than in non-MSI-H tumors. Comparative analyses showed that the overall TIL count was significantly higher in HNPCC/HNPCC-like group, and mucinous type appeared to be more frequent in HNPCC MSI-H tumors than in sporadic MSI-H tumors. However, there was no significant difference in the odds ratio for predicting MSI-H status for any of the analyzed histologic features between HNPCC/HNPCC-like group and sporadic group, indicating that differences between HNPCC and sporadic MSI-H tumors did not significantly impact on the informative value of histology in predicting MSI in the two different clinical settings. TIL counts followed by histologic heterogeneity provided the greatest sensitivity and specificity in predicting MSI status in both HNPCC/HNPCC-like and sporadic cases. Using a stepwise logistic regression model, a formula was generated that could be used to calculate the probability of a colorectal carcinoma being MSI-H based on morphologic features.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14576473     DOI: 10.1097/00000478-200311000-00002

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  73 in total

Review 1.  Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review.

Authors:  Katsuhiko Nosho; Yoshifumi Baba; Noriko Tanaka; Kaori Shima; Marika Hayashi; Jeffrey A Meyerhardt; Edward Giovannucci; Glenn Dranoff; Charles S Fuchs; Shuji Ogino
Journal:  J Pathol       Date:  2010-12       Impact factor: 7.996

Review 2.  The utility of immunohistochemical detection of DNA mismatch repair gene proteins.

Authors:  Jinru Shia; Nathan A Ellis; David S Klimstra
Journal:  Virchows Arch       Date:  2004-09-29       Impact factor: 4.064

3.  Can a gastrointestinal pathologist identify microsatellite instability in colorectal cancer with reproducibility and a high degree of specificity?

Authors:  Eli Brazowski; Paul Rozen; Sara Pel; Ziona Samuel; Irit Solar; Guy Rosner
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

4.  Not all "mucinous carcinomas" are equal: time to redefine and reinvestigate the biologic significance of mucin types and patterns in the GI tract.

Authors:  N Volkan Adsay; David S Klimstra
Journal:  Virchows Arch       Date:  2005-06-08       Impact factor: 4.064

5.  Histology of colorectal adenocarcinoma with double somatic mismatch-repair mutations is indistinguishable from those caused by Lynch syndrome.

Authors:  Jessica A Hemminger; Rachel Pearlman; Sigurdis Haraldsdottir; Deborah Knight; Jon Gunnlaugur Jonasson; Colin C Pritchard; Heather Hampel; Wendy L Frankel
Journal:  Hum Pathol       Date:  2018-05-01       Impact factor: 3.466

6.  Expression patterns of bone morphogenetic protein antagonists in colorectal cancer desmoplastic invasion fronts.

Authors:  George S Karagiannis; Ann Treacy; David Messenger; Andrea Grin; Richard Kirsch; Robert H Riddell; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2014-04-19       Impact factor: 6.603

Review 7.  Clinical significance of microsatellite instability in colorectal cancer.

Authors:  Matthias Kloor; Laura Staffa; Aysel Ahadova; Magnus von Knebel Doeberitz
Journal:  Langenbecks Arch Surg       Date:  2013-09-19       Impact factor: 3.445

8.  Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors.

Authors:  Inti Zlobec; Alessandro Lugli
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

9.  The pathologist's role in rectal cancer patient assessments.

Authors:  Joseph E Willis
Journal:  Clin Colon Rectal Surg       Date:  2007-08

10.  Clinicopathologic Features of Colorectal Carcinoma in HIV-Positive Patients.

Authors:  Carlie Sigel; Marcela S Cavalcanti; Tanisha Daniel; Efsevia Vakiani; Jinru Shia; Keith Sigel
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-05-13       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.